Tesamorelin Compound
Frequently asked questions

Tesamorelin: Questions Answered from the Peer-Reviewed Record

Common questions about Tesamorelin mechanism, safety, dosing, and regulatory status, answered from the published clinical literature.

  • Tesamorelin is a synthetic 44-amino-acid analogue of human growth hormone-releasing hormone (GHRH(1-44)-NH2), modified at the N-terminus with a trans-3-hexenoic acid group. The modification confers resistance to DPP-IV degradation and extends plasma half-life to 26–38 minutes. The FDA approved tesamorelin in 2010 for reduction of excess abdominal fat in HIV-infected adults with lipodystrophy.[1][9]

  • Tesamorelin binds GHRH receptors (GHRH-R) on pituitary somatotrophs, stimulating pulsatile GH secretion. GH elevates hepatic IGF-1 via JAK2/STAT5 signaling. IGF-1 activates hormone-sensitive lipase in visceral adipocytes, producing selective reduction of visceral adipose tissue (VAT) without meaningful change in subcutaneous fat or BMI.[1] IGF-1 raised by 181 µg/L was documented in a 2-week healthy-men study.[10]

  • Yes. The FDA approved tesamorelin under NDA 022505 in November 2010 (Egrifta, 1 mg formulation) for reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. A higher-concentration formulation (Egrifta SV, 2 mg/vial) was approved in 2019. No other indication has received regulatory approval; all other applications remain off-label research.[1]

  • Phase III RCTs in HIV-positive subjects found statistically significant reductions in visceral adipose tissue (VAT): 15.2% reduction versus 5.0% increase in placebo at 26 weeks (Falutz 2007[1]) and 18% sustained reduction at 52 weeks (Falutz 2008[2]). The effect is specific to visceral fat; subcutaneous fat and BMI did not change significantly. VAT reaccumulates within approximately 12 weeks of discontinuation.

  • Phase II and Phase III data show meaningful VAT reduction beginning around week 8 of daily administration, reaching peak effect by week 26 in the pivotal trials. The Falutz 2008 52-week study confirmed that effects are maintained and increase modestly through 12 months of continued administration.[2][3] Effect largely reverses within 12 weeks after discontinuation.[2]

  • VAT reductions documented in the pivotal trials largely reversed within approximately 12 weeks of cessation. The Falutz 2008 and Falutz 2010 trials both demonstrated rapid VAT reaccumulation following treatment discontinuation.[2][3] This finding establishes that the visceral fat benefit is dependent on continued administration.

  • The most common adverse events in clinical trials were injection-site reactions, arthralgias, myalgias, and fluid retention.[1][2] Transient glucose elevation was observed in some subjects. Serious adverse events were uncommon. Absolute contraindications include active malignancy, structural pituitary pathology, pregnancy, and hypersensitivity. IGF-1 and glucose monitoring are recommended throughout treatment.

  • Tesamorelin is contraindicated in active malignancy, pituitary tumor or structural pituitary damage, pregnancy (animal studies showed fetal malformations at therapeutic doses), and hypersensitivity to GHRH analogues.[1][2] Caution is indicated in patients with pre-existing IGF-1 elevation or glucose dysregulation. See the tesamorelin side effects page for the full contraindication summary.

  • The Falutz 2008 52-week and Falutz 2010 12-month extension trials found the adverse event profile at 52 weeks consistent with 26-week data — no new safety signals emerged.[2][3] The 2024 Fourman INSTI trial confirmed 12-month tolerability in a metabolically vulnerable cohort without glycemic worsening.[17]

  • Corticosteroids may blunt the GH secretory response to tesamorelin and reduce efficacy.[1] Co-administration with insulin or anti-diabetic agents may require dose adjustment due to the transient glucose elevation observed in some trials.[11] No other significant drug-drug interactions are documented in the published trial literature.

  • No direct carcinogenicity was demonstrated in completed clinical trials.[1][2] The prescribing information carries a theoretical oncological concern based on GH/IGF-1 pathway stimulation; active malignancy is an absolute contraindication. Post-marketing surveillance has not documented a disproportionate cancer signal attributable to tesamorelin.

  • Phase III trial data and post-marketing experience describe a manageable safety profile. The most common adverse events are injection-site reactions and musculoskeletal complaints; serious events are uncommon. The NIH LiverTox database assigned tesamorelin a Score E (unlikely cause of liver injury).[19] A 12-week type 2 diabetes trial found no significant glucose or HbA1c changes.[11]

  • No. Tesamorelin is a peptide hormone analogue (GHRH analogue) — a 44-amino-acid chain with a fatty acid N-terminal modification — not a steroidal compound.[9] It stimulates endogenous pulsatile GH secretion through the GHRH receptor pathway rather than supplying an exogenous steroid or GH. The mechanism is entirely distinct from anabolic steroid pharmacology.

  • Yes. Tesamorelin is a 44-amino-acid synthetic peptide analogue of human GHRH(1-44)-NH2, with a trans-3-hexenoic acid group added to the N-terminus to extend plasma stability by blocking DPP-IV cleavage.[9] Molecular weight is 5,135.8 Da. It is classified as a peptide hormone analogue in the GHRH class.

  • The FDA-approved indication is reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. Research has also examined hepatic steatosis and NAFLD in HIV patients,[5][6] cognitive function in older adults and mild cognitive impairment,[7] body composition in type 2 diabetes,[11] and efficacy in INSTI-treated HIV patients.[17] All applications outside HIV lipodystrophy remain investigational.

  • Plasma half-life is approximately 26–38 minutes based on population PK modeling.[9] Despite this short plasma half-life, downstream IGF-1 elevation persists for 12–24 hours after a single dose, consistent with prolonged receptor engagement or longer pituitary biological half-life. Once-daily dosing in trial protocols is supported by this pharmacokinetic profile.

  • Published tesamorelin trials did not report significant testosterone elevation as a primary outcome.[1][2][3] The mechanism operates through the GH/IGF-1 axis via GHRH receptor activation and does not directly target gonadal steroidogenesis.

  • Some trials reported modest lean body mass increases alongside VAT reduction; the 2026 meta-analysis of 5 RCTs quantified this at +1.42 kg.[16] Significant muscle hypertrophy was not a primary finding in the pivotal lipodystrophy studies. Lean mass changes appear secondary to body composition recomposition rather than a primary anabolic outcome.

  • No hepatotoxicity signal has been documented. The NIH LiverTox database assigned tesamorelin a Score E (unlikely cause of clinically apparent liver injury).[19] Prospective trials specifically demonstrated hepatic fat reduction, not hepatic injury, as the liver-relevant outcome.[5][6]

  • The FDA-approved Egrifta SV formulation is reconstituted with the supplied sodium chloride diluent. The prescribing information specifies gentle swirling — not shaking — to avoid peptide degradation.[1] Research-grade material is typically reconstituted with bacteriostatic water using the same gentle-swirl technique. The resulting solution should be clear and colorless.

  • The Egrifta SV prescribing information specifies use within 24 hours when stored at 2–8°C after reconstitution.[1] Intact lyophilized vials should be stored at 2–8°C and protected from light before reconstitution. Research-grade protocols typically cite comparable short-term post-reconstitution stability.

  • No head-to-head RCT exists.[9] Tesamorelin has a longer plasma half-life (26–38 min vs ~8–12 min for sermorelin), DPP-IV resistance, and extensive Phase III human evidence for a specific efficacy endpoint (VAT reduction in lipodystrophy). No equivalent Phase III RCT evidence exists for sermorelin in any lipodystrophy or body-composition indication. For the comparative summary, see tesamorelin vs sermorelin.

  • No published trial has studied concurrent tesamorelin plus sermorelin administration.[1] Both act on the same GHRH receptor (GHRH-R), making additive benefit mechanistically uncertain and potentially redundant. The published literature does not support conclusions about co-administration benefit or safety.

  • A secondary analysis of the Stanley 2014 JAMA trial found significant reductions in liver fat alongside VAT reduction.[5] The Stanley 2019 Lancet HIV dedicated NAFLD trial demonstrated a 37% relative liver fat reduction and reduced fibrosis progression.[6] Researchers have noted these findings as a potential investigational avenue in non-HIV populations with NAFLD; however, no non-HIV NAFLD trial has been completed.

  • GH pulse elevation and IGF-1 increase are measurable within hours of a single dose.[10] Meaningful VAT reductions in Phase II and III trial protocols required 8–12 weeks of daily administration to become statistically apparent, with peak effect at 26 weeks.[1][3] Body-composition changes are therefore a weeks-to-months phenomenon, not an acute one.